SIETES :: 92796 citas

Resultados de la búsqueda por ESTIMULANTES BETA-ADRENÉRGICOS REFINAR BÚSQUEDA

1.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors . Ann Intern Med 2019:1. [Ref.ID 103162]

2.

McQuaid J. Asthma takes a hard toll on African-Americans. Can precision medicine ease the burden?. STAT Daily Recap 2019:26 de marzo. [Ref.ID 103064]

3.

Chapman KR, Hurst JR, Frent SM, Larbiq M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:1 de agosto. [Ref.ID 102826]

4.

Busse WW, Bateman ED, Caplan AL, Kelly W, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting ß2-agonists. N Engl J Med 2018;378:2497-505. [Ref.ID 102733]

5.

Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White M, Lazarus SC, Blake KV, Lang JE, Baker WL. Association of inhaled corticosteroids and long-acting ß-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma. A systematic review and meta-analysis. JAMA 2018;319:10 de abril. [Ref.ID 102671]

6.

Krishnan JA, Au DH. Time to converge. FDA Decisions and evidence syntheses for long-acting muscarinic antagonists and SMART in guidelines for the treatment of asthma. JAMA 2018;319:10 de abril. [Ref.ID 102669]

7.

Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]

8.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

9.

Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. A nested case-control study. JAMA Intern Med 2018;178:febrero. [Ref.ID 102529]

10.

Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]

11.

Anónimo. EMA panel recommends approval of GSK’s triple inhaler to treat COPD. DIA Daily 2017:2. [Ref.ID 102050]

12.

Fralick M, Avorn J, Kesselheim AS. The price of crossing the border for medications. N Engl J Med 2017;377:311-3. [Ref.ID 101925]

13.

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

14.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

15.

Velzel J, Vlemmix F, Opmeer BC, Molkenboer JFM, Verhoeven CJ, van Pampus MG, Papatsonis DNM, Bais JMJ, Vollebregt KC, van der Esch L, van der Post JAM, Mol BW, Kok M. Atosiban versus fenoterol as a uterine relaxant for external cephalic version: randomised controlled trial. BMJ 2017;356:i6773. [Ref.ID 101398]

16.

Anónimo. Décongestionnants rhinopharyngés: fibrillations auriculaires. Prescrire 2017;37:24. [Ref.ID 101364]

17.

Anónimo. Indacaterol for chronic obstructive pulmonary disease. Therapeutics Letter 2016:1-2. [Ref.ID 101043]

18.

Fitzgerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Buse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. [Ref.ID 100929]

19.

Bleecker ER, Fitzgerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27. [Ref.ID 100928]

20.

Bush A, Frey U. Safety of long-acting beta-agonists in children with asthma. N Engl J Med 2016;375:889-91. [Ref.ID 100734]